Peptide

Crystagen

Also known as

EDP peptide · Glu-Asp-Pro · EDP tripeptide · immune bioregulator · Khavinson immune cytogen · Crystagen® (commercial bioregulator branding) · Kristagen · T-38 (designation in some originator/vendor lists) · AC-6 (coded Glu-Asp-Pro in some bioregulator catalogs) · thymus/immune short peptide bioregulator · EDG peptide (conflicting vendor sequence claim — see sequence uncertainty) · EAD peptide (search misspelling / informal shorthand) · Glu-Asp-Gly (alternate vendor sequence discussions; often mapped to Chonluten in originator tissue-pair schemes)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	A synthetic three-amino-acid peptide, EDP, discussed as an immune bioregulator for seasonal resilience and longevity calendars.
Preparations differ	Capsules, lingual drops and research vials appear. Synthetic Crystagen is different from Vladonix or Thymalin extract products.

Notes

Crystagen is a short synthetic peptide discussed for immune resilience and longevity calendars. People look for fewer lingering illnesses or better immune markers, rather than an immediate boost. Reports include broad enthusiasm and unchanged laboratory results; capsule calendars and research-vial claims need separate reading.

A three-amino-acid immune bioregulator. Crystagen is associated with Glu-Asp-Pro, abbreviated EDP. The patent defines that sequence; a name on a package does not verify its contents. US8057810B2 — EDP peptide invention and clinical example (Official context · Accessed 2026-09-30)

Capsules, drops and research vials are different forms. Community discussion centers on oral capsules, with lingual drops and subcutaneous vials also appearing. Cytogen refers to a synthetic short peptide; Cytomax to an extract complex. Crystagen, Vladonix and Thymalin are therefore not interchangeable names for one preparation. A List of Peptides and Their Corresponding Effects (Secondhand community claim · Accessed 2026-09-30)

Source context — US8057810B2 — EDP peptide invention and clinical example: Inventor-reported patent examples, not an independently replicated modern clinical trial. Patent does not itself use the Crystagen trade name. Supports EDP reference identity and separately labeled historical context, not current product verification or community doses.

Source context — A List of Peptides and Their Corresponding Effects: Secondhand list, not a user outcome. Its general claim that all Russian studies used injections is not adopted. Original Reddit author/source not separately inspected.

What people notice

Resilience reports	Some accounts describe fewer lingering colds, fewer near-cold days or steadier recovery near a course's end. Sleep, exposure and other peptides also varied.
Little acute feeling	An immediate stimulant-like boost is not the usual description in the saved accounts. Some users look for immune-laboratory changes rather than a sensation.
Unchanged results	One user combined Crystagen, Vilon, Thymogen and Thymulin and reported no significant immune-panel improvement after two months. The result cannot isolate Crystagen.

Notes

Fewer lingering colds or steadier recovery. Community accounts describe seasonal resilience, post-illness support and coping with heavy training. Some describe fewer near-cold days or steadier energy near a course's end. Sleep, exposure and other peptides often change too, so those impressions cannot isolate Crystagen.

Immune markers rather than a stimulant feeling. Users also pursue changes in lymphocytes, a type of immune white blood cell. The old accounts describe little acute kick. Feeling nothing is possible, and a laboratory goal need not produce a noticeable sensation. The mixed experiences below explain why enthusiasm alone is hard to interpret.

A detailed immune experiment produced no significant improvement. The forum author combined Crystagen, Vilon, Thymogen and Thymulin, then retested lymphocyte subsets after two months. Their result cannot isolate Crystagen. They also complained about reactions to one vendor's materials, without establishing Crystagen as the cause. Some research results to share — vpeps immune-panel experiment (Personal report · Accessed 2026-09-30)

Source context — Some research results to share — vpeps immune-panel experiment: Page displays a deleted-topic notice while the opening body and replies remain in the accessible extract. Date not visible. Single unverified multi-agent report; Crystagen route, frequency and course length not explicit. Twenty days is attached to Vilon, not clearly to Crystagen. Vendor complaint does not identify Crystagen as the offending compound.

Doses people talk about

Oral intensive	2 capsules once daily for about 30 days in one calendar. Labels vary; the mentioned 200–400 mcg per capsule cannot be assumed for every product.
Other oral patterns	1–2 capsules daily for 10–20 days, or 1–2 capsules per use, 1–2 times daily for a month. A separate guide describes 200–400 mcg daily; those are different label claims.
Injection charts	1,000–2,000 mcg once daily beneath the skin in vendor charts; older notes list 0.5–1 mg daily. A forum's 1–2 mg amount has no stated route, frequency or separate course.

Notes

Oral intensive: 2 capsules once daily for about 30 days. The retained calendar uses roughly 60 capsules. Other notes mention 200–400 mcg per capsule, but labels differ and may disclose only a peptide complex. Capsule count cannot establish active EDP mass. mcg means micrograms; 1,000 mcg equals 1 mg.

Oral alternatives: 1–2 capsules daily for 10–20 days. A separate retail pattern says 1–2 capsules per administration, 1–2 times daily for a month: up to four capsules daily. Biomogging instead describes 200–400 mcg daily in a 30-day calendar. These remain separate product/guide claims. Biomogging Crystagen protocol and experience summary (Community guide · Accessed 2026-09-30)

Subcutaneous chart: 1,000–2,000 mcg once daily. That is a vendor-chart convention, distinct from older 0.5–1 mg daily notes and a 1.6 mg catalog outlier with sequence uncertainty. The forum experiment reports 1–2 mg Crystagen but does not specify its route, frequency or separate course. None establishes a safe or effective dose. Some research results to share — vpeps immune-panel experiment (Personal report · Accessed 2026-09-30)

Source context — Biomogging Crystagen protocol and experience summary: Biohacking protocol/stack-builder summary with promotional certainty and no identifiable underlying user logs. Dose table contradicts its own capsule arithmetic in one row. Only attributed calendar/amount claims retained; saturation, safety, causality and no-monitoring assurances rejected.

Half-life, onset & duration

Felt onset	Early days are often described as neutral, with some later impressions around days 10–20. No dependable single-agent onset is established.
Felt duration	Residual effects for 2–8 weeks after a course are claimed. Neither a reliable post-course benefit window nor single-dose duration is established.
Half-life	Unknown from the inspected records. About 30 minutes is an unverified internet-chart estimate without a route-specific human measurement.

Notes

Little acute change; some impressions near days 10–20. The retained accounts describe neutral early days and later energy or resilience impressions. No inspected single-agent log establishes a dependable onset. A two-month immune-panel retest is an observation time, not a two-month onset claim. Some research results to share — vpeps immune-panel experiment (Personal report · Accessed 2026-09-30)

Weeks of aftereffects are claimed, without a dependable benefit window. Older discussion places residual effects around 2–8 weeks after a course and attributes them to gene or immune signaling. That explanation is lore, not demonstrated persistence. The reports do not establish single-dose duration or how long any benefit survives stopping.

About 30 minutes appears in an internet chart; it is unverified. Peptide Reference gives this estimate without a route-specific measurement. Older discussion repeats hours-scale action without a precise half-life. Neither establishes human clearance. Half-life measures decline in an amount; it does not measure how long someone feels better. Peptide Reference Crystagen half-life claim (Secondhand community claim · Accessed 2026-09-30)

Source context — Peptide Reference Crystagen half-life claim: Commercially linked internet peptide chart, not an identifiable user log or human PK measurement. Thirty-minute value has no route-specific experiment cited; large oral milligram claims are not validated and are excluded from the dose snapshot.

Cycles people discuss

Short and intensive courses	10–20-day pulses and 20–30-day oral intensives both appear. Repeats range from 2–4 courses yearly to 10-day boosters around every three months.
Longer blocks and breaks	Injection charts extend to 8–12 weeks; some oral guides describe at least a month between intensives. These calendars do not establish an optimal break.

Notes

Short 10–20-day pulses and 20–30-day intensives both appear. Calendars include 2–4 courses yearly, 10-day boosters around every three months, and repeats every 4–6 months. Some guides taper boosters to every 6–12 months after years of use. These are competing calendars, not breaks established from measured human clearance.

Longer injection charts differ from short-course culture. Vendor schedules reach 8–12 weeks; some oral guides specify at least a month between intensives. General bioregulator guides mention a maximum of five intensives yearly. None establishes Crystagen's optimal break, and open-ended daily use is outside the classic pulse pattern.

Stacks

Then Vladonix	A recurring calendar uses one month of synthetic Crystagen followed by about two months of a natural thymus complex. The preparations are different.
Other bioregulators	Vilon, Thymogen, Thymalin and Epitalon appear in immune/longevity combinations; vessel, cartilage and liver peptides appear in broader rotations. These do not establish synergy.

Notes

Crystagen followed by Vladonix is a recurring calendar idea. The retained pattern is one month of synthetic Crystagen, then about two months of a natural thymus complex. Other rotations include Epitalon, Vilon, Thymogen, Thymalin, vessel, cartilage and liver peptides. Multi-organ guides sometimes limit new types to five monthly; that convention does not prove synergy.

Crystagen → Vladonix (cytogen → cytomax): Most-cited immune sequencing—synthetic short course first, then multi-peptide natural thymus complex for a longer phase; ratios/brands of Vladonix vary. [community]

+ Epitalon / pineal leg: Paired with Epitalon (sometimes Pinealon or Endoluten) in longevity calendars (pineal + thymus “first class” style stacks). [community]

+ Vilon (KE) and/or Thymogen (EW): Stacked or compared as the other Thymalin-derived short sequences—attribution of any single-agent effect gets muddy fast. [community] [trial]

+ Thymalin extract: Some users alternate or layer the multi-fraction injectable/historical product with synthetic cytogens—do not assume dose or effect equivalence. [community]

Multi-organ rotations: With vessel (Vesugen/Ventfort), cartilage (e.g., Cartalax/Sigumir talk), liver/GI (Ovagen etc.), bone marrow (Bonomarlot) in full-body bioregulator programs. [community]

Watch for

Reported symptoms	Sparse reports include headache, fatigue, digestive unease and injection-site redness, itching, swelling or tenderness. Illness and other compounds can also contribute.
Identity and quality	EDP and conflicting EDG labels are different sequences. Mislabeling, contamination and nonsterile products remain concerns; capsule counts do not verify active peptide mass.
Immune conditions	Autoimmune disease, transplant and immunotherapy contexts feature in community cautions. The accounts do not establish interaction safety or justify treating infections or cancer.

Notes

Sparse reports include headache, fatigue, GI unease and injection-site irritation. The retained record includes redness, itching, swelling and tenderness. These symptoms may involve illness, other compounds or product handling. Quiet adverse-event discussion cannot establish long-term safety.

Identity and immune context matter. EDP and conflicting EDG labels describe different sequences. Contamination, underdosing and nonsterile products remain concerns. Community cautions include autoimmune disease, transplant and immunotherapy contexts; these reports cannot establish a specific interaction or justify treating infections or cancer.

Full notes

What Crystagen is

A three-amino-acid immune bioregulator. Crystagen is associated with Glu-Asp-Pro, abbreviated EDP. The patent defines that sequence; a name on a package does not verify its contents. Official context
Capsules, drops and research vials are different forms. Community discussion centers on oral capsules, with lingual drops and subcutaneous vials also appearing. Cytogen refers to a synthetic short peptide; Cytomax to an extract complex. Crystagen, Vladonix and Thymalin are therefore not interchangeable names for one preparation. Community Longecity

What people hope to notice

Fewer lingering colds or steadier recovery. Community accounts describe seasonal resilience, post-illness support and coping with heavy training. Some describe fewer near-cold days or steadier energy near a course's end. Sleep, exposure and other peptides often change too, so those impressions cannot isolate Crystagen. Community Community
Immune markers rather than a stimulant feeling. Users also pursue changes in lymphocytes, a type of immune white blood cell. The old accounts describe little acute kick. Feeling nothing is possible, and a laboratory goal need not produce a noticeable sensation. The mixed experiences below explain why enthusiasm alone is hard to interpret. Community

Doses people discuss

Reported amounts, not instructions. Subcutaneous means beneath the skin; oral and injected amounts are not equivalent.

Oral intensive: 2 capsules once daily for about 30 days. The retained calendar uses roughly 60 capsules. Other notes mention 200–400 mcg per capsule, but labels differ and may disclose only a peptide complex. Capsule count cannot establish active EDP mass. mcg means micrograms; 1,000 mcg equals 1 mg. Community
Oral alternatives: 1–2 capsules daily for 10–20 days. A separate retail pattern says 1–2 capsules per administration, 1–2 times daily for a month: up to four capsules daily. Biomogging instead describes 200–400 mcg daily in a 30-day calendar. These remain separate product/guide claims. Community Community guide
Subcutaneous chart: 1,000–2,000 mcg once daily. That is a vendor-chart convention, distinct from older 0.5–1 mg daily notes and a 1.6 mg catalog outlier with sequence uncertainty. The forum experiment reports 1–2 mg Crystagen but does not specify its route, frequency or separate course. None establishes a safe or effective dose. Community Personal report

Half-life

About 30 minutes appears in an internet chart; it is unverified. Peptide Reference gives this estimate without a route-specific measurement. Older discussion repeats hours-scale action without a precise half-life. Neither establishes human clearance. Half-life measures decline in an amount; it does not measure how long someone feels better. Peptide Reference Community

Onset: when a change is noticed

Little acute change; some impressions near days 10–20. The retained accounts describe neutral early days and later energy or resilience impressions. No inspected single-agent log establishes a dependable onset. A two-month immune-panel retest is an observation time, not a two-month onset claim. Community Personal report

Duration: how long a change lasts

Weeks of aftereffects are claimed, without a dependable benefit window. Older discussion places residual effects around 2–8 weeks after a course and attributes them to gene or immune signaling. That explanation is lore, not demonstrated persistence. The reports do not establish single-dose duration or how long any benefit survives stopping. Community

Cycles and breaks

Short 10–20-day pulses and 20–30-day intensives both appear. Calendars include 2–4 courses yearly, 10-day boosters around every three months, and repeats every 4–6 months. Some guides taper boosters to every 6–12 months after years of use. These are competing calendars, not breaks established from measured human clearance. Community Community
Longer injection charts differ from short-course culture. Vendor schedules reach 8–12 weeks; some oral guides specify at least a month between intensives. General bioregulator guides mention a maximum of five intensives yearly. None establishes Crystagen's optimal break, and open-ended daily use is outside the classic pulse pattern. Community

Good to know

Sparse reports include headache, fatigue, GI unease and injection-site irritation. The retained record includes redness, itching, swelling and tenderness. These symptoms may involve illness, other compounds or product handling. Quiet adverse-event discussion cannot establish long-term safety. Community
Identity and immune context matter. EDP and conflicting EDG labels describe different sequences. Contamination, underdosing and nonsterile products remain concerns. Community cautions include autoimmune disease, transplant and immunotherapy contexts; these reports cannot establish a specific interaction or justify treating infections or cancer. Community

From community discussion

A positive oral endorsement has no measured endpoint. In a long-Covid thread, one commenter favored Crystagen for thymus support and reported no bad reactions across six years of varied peptides. No specific Crystagen symptom change, dose or course was supplied. That experience supports an endorsement, not a safety guarantee. Personal report
A detailed immune experiment produced no significant improvement. The forum author combined Crystagen, Vilon, Thymogen and Thymulin, then retested lymphocyte subsets after two months. Their result cannot isolate Crystagen. They also complained about reactions to one vendor's materials, without establishing Crystagen as the cause. Personal report
Emergency-reserve interest is different from having tried it. A Longecity creator kept Crystagen alongside vitamins, fasting and red-light habits for possible future illness. The promotional post contains no treatment outcome. Its emergency or autoimmune suggestions are not evidence that Crystagen helps either situation. Longecity
Crystagen followed by Vladonix is a recurring calendar idea. The retained pattern is one month of synthetic Crystagen, then about two months of a natural thymus complex. Other rotations include Epitalon, Vilon, Thymogen, Thymalin, vessel, cartilage and liver peptides. Multi-organ guides sometimes limit new types to five monthly; that convention does not prove synergy. Community Community
Meal timing and form changes complicate comparisons. Oral discussion varies between with-food and before-meal use; lingual schedules use multiple administrations daily, without a reliable drop-to-mcg conversion here. Injection talk favors a consistent daily time. No response after courses need not mean an amount was too low. Community Community

Where the immune claims come from

The 82% versus 56% figure comes from a patent example. It describes 38 treated and 32 comparison patients aged 62–83, with irradiation-related or age-related immune decline and conventional care. It is an inventor-reported result, not a community success rate or proof for today's capsules. Official context